RedHill Biopharma, established in 2009, is a pharmaceutical company focused primarily on development of late clinical-stage new, improved and patented formulations of existing drugs, with preference to a 505(b)(2)* regulatory path.
h
RedHill’s pipeline currently includes 6 clinical stage drug candidates under development addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.
h
RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification and further reduction of risk.
h
RedHill’s experienced management team, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
* 505 (b)(2) is potentially a more convenient and lower cost US regulatory approval route intended for certain new formulations of existing drugs, allowing reference to the latter’s existing data.